Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY24 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $2.40-2.50 for the period, compared to the consensus EPS estimate of $2.45. The company issued revenue guidance of $16.10-16.50 billion, compared to the consensus revenue estimate of $16.27 billion. Teva Pharmaceutical Industries also updated its FY 2024 guidance to 2.400-2.500 EPS.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TEVA shares. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Trading Down 2.3 %

Shares of NYSE:TEVA opened at $17.10 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The company’s 50-day moving average price is $17.94 and its 200 day moving average price is $17.10. The company has a market cap of $19.37 billion, a PE ratio of -20.11, a P/E/G ratio of 1.25 and a beta of 0.87. Teva Pharmaceutical Industries has a fifty-two week low of $8.55 and a fifty-two week high of $19.31.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. The firm had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.08 billion. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 41.43%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.34 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.